Breast cancer: Post-traumatic stress disorder - Prevalent and persistent

Nature Reviews Clinical Oncology

Volumn 10, Issue 5, 2013, Pages 252-254

  Palesh, Oxana ^a   Koopman, Cheryl ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN AMERICAN; ASIAN AMERICAN; BREAST CANCER; BREAST METASTASIS; DISTRESS SYNDROME; HUMAN; NOTE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RACE DIFFERENCE; SUPPORT GROUP; UNITED STATES;

HUMANS; SEVERITY OF ILLNESS INDEX; STRESS DISORDERS, POST-TRAUMATIC;

EID: 84877584949     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.49     Document Type: Note

References (10)

1. Rummel, M.J.et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas; An open-label, multicentre, randomised, phase, 3 non-inferiority trial Lancet http://dx.doi.org/10.1016/S0140-6736(12)61763-2
2. National Cancer Institute. SEER Stat Fact Sheets: Lymphoma [online], http://seer.cancer.gov/statfacts/html/lymph.html (2012
3. Friedberg, J., W.et al.Follicular lymphoma in the, United States: First report of the national LymphoCare study. J. Clin. Oncol. 27, 1202-1208 (2009
4. SallesG.et al. Rituximab maintenance for 2, years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy RIMA); A phase, 3, randomised controlled trial Lancet 377, 42-51 (2011
5. Buske, C.et al.Front-line combined immuno-chemotherapy (R-CHOP) significantly improves the time to treatment failure and overall survival in elderly patients with advanced stage, follicular lymphoma -results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG.). Blood (ASH Annual Meeting Abstracts) 108, a482 (2006
6. van Oers, M., H.et al.Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in, patients both with and without rituximab during induction: Results of a prospective randomized phase, 3 intergroup trial. Blood 108, 3295-3301 (2006
7. Malard, F.et al.Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or, lenalidomide. Biol. Blood Marrow Transplant. 18, 314-317 (2012
8. Schmidt-Hieber, M.et al.Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in, vitro. J. Cancer Res. Clin. Oncol. 135, 227-234 (2009
9. Kahl, B., S.et al.Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: Results, from a multicenter study. Cancer 116, 106-114 (2010
10. Vidal, L.et al.Rituximab maintenance for the treatment of patients with follicular lymphoma: Systematic review and meta-analysis of randomized trials. J. Natl Cancer Inst. 101, 248-255 (2009